Incorrect use of colony stimulating factors (CSF) can add unnecessary cost to cancer treatments and adverse events to patients. We conducted an epidemiological study to assess the correlation between CSF use recommendations issued by the Brazilian Regulatory Agency of Health (ANS) and technical recommendations stated by international guidelines. We also analyzed the main reasons for not recommending the use of CSF, in patients during chemotherapy.
1
Grades 3 and 4 neutropenia are defined as "neutrophil count below 1,000 cells/ mm 3 and 500 cell/mm 3 " respectively. These real-world data allowed us to identify that there is still an important knowledge gap regarding the correct use of CSF. The most common misconceptions or unsound conducts detected were:
We also observed that there is a high rate of agreement between the regulatory recommendations (ANS) and the scientific ones (medical literature and guidelines).
Almost three quarters of the requests are for one specific brand of CSF.
Despite the vast amount of information on febrile neutropenia available both in printing and online, there is a need to further capacitate physicians on this topic. Continual medical education programs must address this gap, to avoid damage to patients and waste of resources for healthcare systems. 
RESULTS
In the aforementioned period, 440 requests for CSF corresponding to 322 patients were input in the Evidências _ Kantar Health database. Some patients had only one request for the medication, while others had several requisitions.
Regarding requests according to geographical region, there were: 141 from the South, 205 (Southwest), 26 (Central-West), 68 (Northeast) and none from the North Region (see Figure 1) .
As for tumor types, CSF was requested mainly for breast cancer (84 requests), non-Hodgkin lymphoma (83), leukemias (50) and myelodisplastic syndrome/myeloma (43).
CSF was also requested for patients diagnosed with: gynecological tumors (28 requests), Hodgkin's lymphoma (25), colon cancer (19), Ewing's sarcoma (13), esophageal/gastric tumors (11) and urological cancers (22). Forty-four requests were distributed among other types of cancer (see Table 1 and Figure 2 ).
Regarding the purpose of chemotherapy treatments in which CSF were added: 104 were adjuvant therapies, 16 neoadjuvant, 165 palliative, 134 curative (hematological treatments) and 21 bone marrow transplantations (see Figure 3) .
Except for requests linked to bone marrow transplantations, which are not regulated by RN349, all the other ones were assessed:
Request of CSF for patients in chemotherapy with less than 20% risk of febrile neutropenia and without complications (75 requests, 37.5% of denials) (see Figure 4) .
First measure of treatment for neutropenic patients in palliative chemotherapy (52 requests, 26% of denials).
Complete blood count (CBC) collected on chemotherapy's nadir (7 to 10 days post infusion) to justify the need for CSF (50 requests, 25% of all denials). That was a regular practice in some of the analyzed areas.
CBC without signs of neutropenia (neutrophils were 1,500 cells/mm 3 ) (9 requests, 4.5% of denials).
Treatment of uncomplicated low-risk febrile neutropenia (10 requests, 5% of denials).
CSF requested for patients who were not receiving chemotherapy or were about to be submitted to orthopedic surgery (4 requests, 2% of denials)
Only 17 requests (3.8%) were for Neulastin®, 110 (24.8%) were for filgrastin (no brand specification) and 313 (71.4%) for Granulokine®. 
General Aspects

Origins Tumor Types Treatment Purpose
Agreement with Guidelines and ANS
Reasons for Pre-authorization Denial
Class of CSF Requested
